Daniel J. Starks - Apr 28, 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role: Director
Signature: /s/ Daniel J. Starks by Jessica H. Paik, Attorney-in-Fact
Stock symbol: ABT
Transactions as of: Apr 28, 2023
Transactions value $: -$5,551,193
Form type: 4
Date filed: 5/2/2023, 08:04 PM
Previous filing: Oct 31, 2022
Next filing: Jul 28, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABT	Common shares without par value	Award	$0	+1.82K	+0.03%	$0.00	6.88M	Apr 28, 2023	Direct	F1
transaction	ABT	Common shares without par value	Sale	-$5.17M	-46.5K	-0.68%	$110.97	6.83M	May 2, 2023	Direct	F2
transaction	ABT	Common shares without par value	Sale	-$386K	-3.45K	-0.05%	$111.75	6.83M	May 2, 2023	Direct	F3
holding	ABT	Common shares without par value						258	Apr 28, 2023	Alynne Starks 2012 Irrevocable Trust	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABT	Option (right to buy)	Award	$0	+8.14K		$0.00	8.14K	Apr 28, 2023	Common Shares	8.14K	$110.12	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.51 to $111.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.58 to $111.90, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4	Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
F5	Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The sale transactions disclosed under Table I were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).